We are live on ! Find out more
SLN

Silence Therapeutics

54 hedge funds and large institutions have $96.4M invested in Silence Therapeutics in 2025 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.18% less ownership

Funds ownership: 66.02%65.84% (-0.18%)

6% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 16

2% less funds holding

Funds holding: 5554 (-1)

11% less capital invested

Capital invested by funds: $108M → $96.4M (-$11.6M)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $6K

Holders
54
Holders Change
-1
Holders Change %
-1.82%
% of All Funds
0.71%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
6
Increased
15
Reduced
16
Closed
7
Calls
Puts
$6K
Net Calls
-$6K
Net Calls Change
-$131K

SLN Hedge Fund Activity: Q3 2025 in Review

54 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q3 2025, worth a combined $96.4M — down 11% from $108M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of SLN and 6 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 15 added.

The largest buyer was Millennium Management, adding an estimated $555K. The largest seller was BlackRock, cutting an estimated $591K.

  • 54 institutional investors held Silence Therapeutics (SLN) as of Q3 2025, down from 55 in Q2 2025.
  • Funds reported $96.4M of Silence Therapeutics stock for Q3 2025, down 11% quarter-over-quarter.
  • 6 funds opened new Silence Therapeutics positions in Q3 2025 and 7 closed out, a net change of -1 holder.
  • The largest Silence Therapeutics buyer in Q3 2025 was Millennium Management, an estimated $555K added.
  • The largest Silence Therapeutics seller in Q3 2025 was BlackRock, an estimated $591K sold.

Based on aggregated 13F filings for Q3 2025.